Expert opinions regarding neuro-microcirculatory, vestibular and labyrinthine dynamics in benign paroxysmal positional vertigo

Rajesh Benny


Benign paroxysmal positional vertigo (BPPV) is a common vestibular disorder and a leading cause of peripheral vertigo in adults. The current treatment with repositioning maneuvers still leaves some residual dizziness in a significant proportion of patients with BPPV. The role of neuro-microcirculatory, vestibular, and labyrinthine dynamics needs to be evaluated. Eighty leading neurologists and otolaryngologists from across India participated in advisory board meetings to debate on altered neuro-microcirculatory, vestibular, and labyrinthine dynamics in BPPV. Betahistine when used in conjunction with Epley maneuver was considered to be a safe treatment. Betahistine can be used as monotherapy in patients with BPPV who are deemed unfit to undergo canalolith repositioning maneuvers. Betahistine provides short-term relief from acute symptoms associated with BPPV by improving microcirculation in the labyrinth and improves vestibular compensation, thereby providing long-term benefit. Betahistine also improves outcomes in combination with canalolith repositioning maneuvers. Experts unanimously agreed upon the role of betahistine in providing better vestibular health and in-turn, recovery from vertigo.


Betahistine, Epley maneuver, Dizziness, Vestibular compensation

Full Text:



Wu P, Cao W, Hu T, Li H. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial. BMJ Open. 2019;9:e026711.

Kameswaran M, Pujari S, Singh J, Basumatary LJ, Sarda K, Pore R. Clinicoetiological pattern and pharmacotherapy practices in patients with new onset vertigo: findings from a prospective multicenter registry in India. Int J Otolaryngol Head Neck Surg. 2017;3:404-13.

Tari AD, Kumar S. The effect of postural stability exercises in benign paroxysmal positional vertigo: Pre-post-experimental study. Physiotherapy. 2017;11:66-70.

Wada M, Naganuma H, Tokumasu K, Hashimoto S, Ito A, Okamoto M. Arteriosclerotic changes as background factors in patients with peripheral vestibular disorders. Int Tinnitus J. 2008;14:131-4.

Agrup C, Gleeson M, Rudge P. The inner ear and the neurologist. J Neurol Neurosurg Psychiatry 2007;78:114-22.

Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston L, Cass S et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2008;139:S47-81.

Yetiser S. Review of the pathology underlying benign paroxysmal positional vertigo. J Int Med Res 2020;48:300060519892370.

Şahin E, Deveci I, Dinç ME, Özker BY, Biçer C, Erel O. Oxidative status in patients with benign paroxysmal positional vertigo. J Int Adv Otol. 2018;4:99-303.

Epley JM. The canalith repositioning procedure for treatment of benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 1992;107:399-404.

Giommetti G, Lapenna R, Panichi R, Mobaraki PD, Longari F, Ricci G et al. Residual dizziness after successful repositioning maneuver for idiopathic benign paroxysmal positional vertigo: A review. Audiol Res. 2017;7:178.

Parfenov VA, Golyk VA, Matsnev EI, Morozova SV, Melnikov OA, Antonenko LM et al. Effectiveness of betahistine (48 mg/day) in patients with vestibular vertigo during routine practice: The VIRTUOSO study. PLoS One. 2017;12:e0174114.

Stambolieva K, Angov G. Effect of treatment with betahistine dihydrochloride on the postural stability in patients with different duration of benign paroxysmal positional vertigo. Int Tinnitus J. 2010;16:32-36.

Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001;15:853-70.

Berisavac II, Pavlović AM, Trajković JJZ, Šternić NMC, Bumbaširević LJB. Drug treatment of vertigo in neurological disorders. Neurol India. 2015;63:933-9.

Biswas A. Betahistine. Indian J Otolaryngol Head Neck Surg. 1997;49:179-87.

Laurikainen E, Miller JM, Nuttall AL, Quirk WS. The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol. 1998;255:119-23.

Laurikainen E, Miller JF, Pyykkö I. Betahistine effects on cochlear blood flow: From the laboratory to the clinic. Acta Otolaryngol Suppl. 2000;544:5-7.

Suga F, Snow JB. Cochlear blood flow in response to vasodilating drugs and some related agents. Laryngoscope. 1969;79:1956-79.

Della Pepa C, Guidetti G, Eandi M. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. Acta Otorhinolaryngol Ital. 2006;26:208-15.

Kaur J, Shamanna K. Management of benign paroxysmal positional vertigo: a comparative study between Epleys manoeuvre and betahistine. Int Tinnitus J. 2017;21:30-4.

Cavaliere M, Mottola G, Iemma M. Benign paroxysmal positional vertigo: a study of two manoeuvres with and without betahistine. Acta Otorhinolaryngol Ital. 2005;25:107-12.

Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2012;146:104-8.